BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Ravulizumab: trial readouts and FDA decisions

0 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 3 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Alexion Pharmaceuticals, Inc., Regeneron Pharmaceuticals. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-09-28P3Regeneron Pharmaceuticals REGNNCT05133531 A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNHParoxysmal Nocturnal Hemoglobinuriacompleted202
2026-07-15 est.P3Alexion Pharmaceuticals, Inc.NCT05644561 Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia Gravis; gMGactive not recruiting12
2026-06-22 est.P2/P3Alexion Pharmaceuticals, Inc.NCT05346354 Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSDNeuromyelitis Optica Spectrum Disorderactive not recruiting12

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.